EUVIMEDEUVIMED entdecken
Crossref

How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians

Ameet Sarpatwari iD, Zhigang Lu, Massimiliano Russo iD, Heidi Zakoul, Su Been Lee, Gita A Toyserkani iD, Esther H Zhou, Cynthia LaCivita, Katherine Hyatt Hawkins Shaw, Laura Zendel, Gerald J Dal Pan iD, Aaron S Kesselheim iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Ameet Sarpatwari und 11 weiteren Autor:innen. Beteiligte Einrichtung: Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Wo…. Hauptthemen laut MEDLINE: Practice Patterns, Physicians', Risk Evaluation and Mitigation, Physicians. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: FDA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The US Food and Drug Administration can require risk evaluation and mitigation strategy (REMS) programs for prescription drugs to ensure the benefits of use outweigh the risks. We conducted a national survey of physicians' experiences prescribing eight REMS‐covered drugs: (1) ambrisentan; (2) bosentan; (3) clozapine; (4) isotretinoin; (5–7) the multiple myeloma (MM) drugs lenalidomide, pomalidomide, thalidomide; and (8) sodium oxybate. Between May 2022 and January 2023, we surveyed 5,331 physician prescribers of these drugs, and 1,295 (24%) returned surveys (range: 149 for bosentan to 226 for MM drugs). Although 765 (68%) respondents thought the certification process provided useful drug information, 757 (67%) wanted materials to include benefit data and 944 (84%) non‐REMS‐related risk data. A majority (704, 63%) thought the safe use requirements facilitated discussion with patients, but a similar number (637, 57%) attributed delayed medication access to these requirements. In multivariable modeling, MM drug and isotretinoin respondents were less likely than sodium oxybate respondents to agree that the certification process provided useful drug information (MM drug: odds ratio (OR) = 0.37, 95% confidence interval (CI) = 0.25–0.55; isotretinoin: OR = 0.39, 95% CI = 0.25–0.61), and isotretinoin, clozapine, and bosetan respondents were more likely than sodium oxybate respondents to agree that the safe use requirements often delayed medication access (isotretinoin: OR = 5.83, 95% CI = 3.70–9.19; clozapine: OR = 1.65, 95% CI = 1.08–2.54; bosentan: OR = 1.78, 95% CI = 1.12–2.85). Most physicians believe REMS programs convey useful drug safety information and facilitate discussion with patients but also seek information on benefits and non‐REMS‐related risks and better integration of REMS processes into clinical workflows.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Practice Patterns, Physicians'Risk Evaluation and MitigationPhysiciansHumansUnited StatesSurveys and QuestionnairesUnited States Food and Drug AdministrationPrescription DrugsMaleFemaleRisk Assessment

Substanzen

Prescription Drugs

Autor:innen und Institutionen

  • Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.

ORCID-Profile: Ameet Sarpatwari, Massimiliano Russo, Gita A Toyserkani, Gerald J Dal Pan, Aaron S Kesselheim

Förderung

  • FDA HHS

Zitieren

APA

Sarpatwari, A., Lu, Z., Russo, M., Zakoul, H., Lee, S. B., Toyserkani, G. A., Zhou, E. H., LaCivita, C., Shaw, K. H. H., Zendel, L., Dal Pan, G. J., & Kesselheim, A. S. (2024). How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3189

Vancouver

Sarpatwari A, Lu Z, Russo M, Zakoul H, Lee SB, Toyserkani GA, et al. How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3189

BibTeX
@article{Sarpatwari2024,
  author = {Sarpatwari, Ameet and Lu, Zhigang and Russo, Massimiliano and Zakoul, Heidi and Lee, Su Been and Toyserkani, Gita A and Zhou, Esther H and LaCivita, Cynthia and Shaw, Katherine Hyatt Hawkins and Zendel, Laura and Dal Pan, Gerald J and Kesselheim, Aaron S},
  title = {How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3189}
}
Kostenlos starten →